Sagimet Biosciences (STU:0O2) All Taxes Paid

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:0O2 Sagimet Biosciences Inc STU:0O2
38 GF Score
Price €6.26
GF Value €5.69
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Sagimet Biosciences All Taxes Paid?

All Taxes Paid only applicable to companies reporting Cash Flow from Operations in direct method.

STU:0O2
38GF Score
Sagimet Biosciences Inc STU:0O2
All Taxes Paid is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sagimet Biosciences (STU:0O2) Overvalued in 2026?

Based on GuruFocus' analysis, Sagimet Biosciences stock appears to be overvalued. The current stock price of €6.26 is trading 10% above its estimated GF Value™ of €5.69. GuruFocus considers Sagimet Biosciences to be Fairly Valued.

Key valuation signals for STU:0O2:

  • All Taxes Paid:
  • GF Value™: €5.69 vs. price of €6.26 (10% above fair value)
  • GF Score™: 38/100 with 2 warning signs

No single metric tells the full story. See the STU:0O2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sagimet Biosciences Business Description

Other Exchanges SGMT:USA
Address 155 Bovet Road, Suite 303, San Mateo, CA, USA, 94402
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
38GF Score

Get the complete analysis for STU:0O2

All Taxes Paid is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.26
Price
€5.69
GF Value